Genetically engineered antibodies for diagnostic pathology.
Antibody genes can be cloned, genetically manipulated, and expressed in both homologous and heterologous expression systems to produce viable antigen-binding proteins complete with natural effector functions. Manipulation of antibody genes permits the expression of fusion proteins or truncated proteins that retain antigen-binding activity. The new antibody technologies are becoming increasingly sophisticated, permitting the alteration of antigen-binding responses, the transfer of antigen specificity between antibodies, and the expression of minimal-size antigen-binding protein domains. These new molecules have been made mostly for studies on function or to provide molecules suited for in vivo diagnosis and therapy; very few have been specifically designed for, or used for, diagnostic histopathology. We describe here the adaptation of small antibody derivatives for use in immunohistochemistry. Molecules suitable for this purpose need only to possess specific antigen-binding ability and some means of detection of antigen-bound material. Detection could be by recognition of a genetically fused flag or tag epitope, by the fusion of an enzyme whose activity can be assayed, or by fusion with a protein that can interact with pre-existing histopathological reagents.
Tumour Targeting Laboratory, ICRF Oncology Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
R A
RA
Spooner
S
S
Murray
G
G
Rowlinson-Busza
M P
MP
Deonarain
A
A
Chu
A A
AA
Epenetos
D000818:Animals; D000906:Antibodies / Q000235:genetics*; D018033:Antibodies, Bispecific; D006801:Humans; D007135:Immunoglobulin Variable Region / Q000235:genetics; D015202:Protein Engineering / Q000379:methods*; D011993:Recombinant Fusion Proteins; D014183:Transplantation, Heterologous / Q000276:immunology; D014407:Tumor Cells, Cultured / Q000276:immunology
D000906:Antibodies; D018033:Antibodies, Bispecific; D007135:Immunoglobulin Variable Region; D011993:Recombinant Fusion Proteins